Revolutionizing acne care, for a clearer tomorrow
Indomo is a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics.
We aim to shift today’s in-office standard of care into the hands of patients at home by combining our drug candidate, DT-001, with our novel intradermal self-injection device, the ClearPen.
This drug-device combination is designed to allow patients to access intralesional acne injections whenever and wherever they need them.
Indomo’s products are under development and have not been evaluated by the FDA. If you are interested in participating in a registered clinical trial you can sign up here to be added to our consideration list.
the science
The American Academy of Dermatology strongly recommends the use of intralesional triamcinolone acetonide injections for the resolution of moderate to severe acne lesions.
Unlike topicals, when a physician injects triamcinolone acetonide, it ensures that the drug gets directly to the site of inflammation quickly.
50+ years of real world evidence
This treatment has 50+ years of real-world clinical experience and is recommended by the American Academy of Dermatology as a first-line treatment for inflammatory lesions.
Designed with the patient in mind
Indomo’s goal is to empower patients to perform this treatment safely at home by controlling dosage, depth, and volume of injection.
Replicating in-office procedure
Indomo has performed two investigator-led trials to evaluate the equivalence between provider injection and patient self-injection.
Lesion improvement
Following treatment
.svg)
world-class team
Our team combines experts in drug delivery, consumer health, dermatology, & acne.
Together we are on a mission to empower patients with the best dermatological care.
Built by the best, with backgrounds from:
